Navigation Links
Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
Date:2/29/2012

BOSTON, MA February 29, 2012 TREM Rx, Inc., a biotechnology company with a proprietary technology platform for novel vaccines delivered to the skin, announced today the results of an in vivo preclinical study that shows, for the first time, that powerful cells of the immune system called TREMs (T Resident Effector Memory cells) prevalent in the skin can mediate a protective immune response that is far stronger than memory T cells that circulate in the bloodstream. The study was published in today's online edition of Nature and was led by TREM Rx scientific founder, Dr. Thomas S. Kupper, the Thomas B. Fitzpatrick Professor of Dermatology at Harvard Medical School, and chair of Dermatology at Brigham and Women's Hospital and the Dana Farber Cancer Institute.

This research and previous work by Dr. Kupper's group demonstrated that a stronger generalized T cell immune response, and in particular a more robust TREM response, can be produced by delivering a viral vaccine vector to the upper skin tissues, as compared to below the skin or into the muscle. This new research reveals why novel vaccines administered to upper layers of the skin in preclinical models have demonstrably better preventative and therapeutic efficacy over conventional vaccine injection into the muscles or bloodstream. TREM Rx has exclusive rights to this vaccine-relevant intellectual property as the basis for the company's proprietary technology platform for developing novel vaccines.

"Conventional vaccines are typically focused on optimizing the B cell arm of the immune system to create disease-fighting antibodies. In contrast, this study shows that a more effective path to immunity may be to engage this newly discovered part of the T cell arm of the immune system through a population of powerful immune cells that we now know reside in the skin, lung, gut, and other epithelial tissues," said Thomas S. Kupper, MD, senior author of the Nature paper.

"Putting this research in historical context, it helps explain the uniquely powerful efficacy of the first successful vaccine developed for smallpox by Jenner in 1796," said Kupper. "Syringes had not yet been invented, so Jenner administered the first vaccine by disrupting the upper layers of skin with a specialized needle, a process similar to how the vaccinia virus was delivered in our study. It is worth remembering that the smallpox vaccine remains the most effective vaccine in the history of medicine, resulting in the elimination of smallpox in human populations."

In the preclinical study in Nature, vaccinia virus delivered to the skin was found to rapidly recruit viral-specific T cells, called TREMs (T Resident Effector Memory cells), not just to the infected site, but also to all areas of the skin. These TREMs remained in skin, and provided rapid and effective protection against a second infection from the same virus. While skin was used as a model system in the study, the results are relevant to epithelial cells in the lungs, GI tract, and other epithelial tissues that are sites of viral entry to the body.

The findings of this study challenge immunological dogma by suggesting that the most important elements of T cell memory and immunity to infectious diseases may reside in skin and other epithelial tissues mediated by TREMs, rather than by circulating T or B cells in the blood. With regard to the impact on vaccine design and delivery, the study suggests that vaccines to generate TREM can be optimized by delivery through epithelial tissues, for a potentially more effective immune response than is achieved with conventional vaccine injection.

"This groundbreaking research provides a major opportunity to develop a new class of vaccines with improved preventative and therapeutic efficacy that can potentially have a major impact on human health," said Eric Stromquist, president of TREM Rx. "We are committed to translating this new understanding of protective immunity to the design of novel vaccines for a wide range of applications, including important infectious diseases and cancers."


'/>"/>

Contact: Barbara Yates
barbara@theyatesnetwork.com
781-258-6153
The Yates Network
Source:Eurekalert

Related biology technology :

1. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
2. Discovery opens door to low-cost negative refraction, new products and industries
3. AnaptysBio Announces New Strategic Antibody Discovery
4. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
5. Discovery of a dark state could mean a brighter future for solar energy
6. Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
7. Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
8. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
9. GlaxoSmithKline and the University of Edinburgh Agree to Collaborative Partnership for Drug Discovery
10. MIABE standard opens up new opportunities in drug discovery
11. Malaria discovery gives hope for new drugs and vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... Therapeutics Summit ( http://www.paintherapeuticsummit.com ) is coming to San Diego, CA on September ... conference to learn about the latest advances in the treatment of various types ...
(Date:4/27/2017)... ... April 27, 2017 , ... The ... Communication Award goes to Jayson Lusk, a consummate communicator who promotes agricultural science ... advocate for science, as he explains how innovation and growth in agriculture are ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led ... phase I clinical trials comes to Tampa, San Francisco and Boston in 2017. ... representing FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular ...
(Date:4/26/2017)... 2017  Genisphere LLC, provider of the 3DNA ... collaborative and sponsored research agreement with the University ... The overall goal of the partnership is to ... designs and formulations after in vivo ... vasculature as well as inflammatory responses, demonstrating various ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):